DNDN Related Earnings News
-
UPDATE: Stifel Nicolaus Downgrades Dendreon (DNDN) to Sell
-
Dendreon Corp (DNDN) Reports In-Line Q1 Loss of 48c/Share
-
Bearish Analyst Comments on Dendreon (DNDN)
-
Dendreon Corp (DNDN) Posts Q4 Loss of 26c/Share
-
Cantor Fitzgerald Raises Estimates and PT on Dendreon (DNDN) Ahead of Q4
-
Dendreon (DNDN) Q4 Revs Top Views
-
Dendreon Corp (DNDN) Posts Narrower than Expected Q3 Loss of 33c/Share
-
Dendreon (DNDN) Sees 25M of Charges on Recent Job Cuts
-
Cantor Fitzgerald Maintains a 'Hold' on Dendreon (DNDN); Near Term Not Pretty
-
Barclays Cuts Numbers on Dendreon (DNDN); Facing An Uphill Battle Just To Gain Traction
-
Canaccord Genuity Cuts PT and Estimates on Dendreon (DNDN); Going Off the Rails on a Crazy Train
-
Jefferies Cuts Numbers on Dendreon (DNDN) After Poor Q2
-
Baird Lower Numbers on Dendreon (DNDN) But Says Restructuring the Right Move
-
Dendreon Corp (DNDN) Misses Q2 EPS by 2c
-
Maxim Upgrades Dendreon (DNDN) as the Street is 'Too Bearish' Ahead of Q2 Results
-
RBC Capital Negative on Dendreon (DNDN) Ahead of Q2 Results
-
Wedbush Reiterates an 'Underperform' on Dendreon (DNDN); New Treatments in Prostate Cancer Could Leave Provenge Behind
-
Canaccord Genuity Maintains a 'Hold' on Dendreon (DNDN) After Meeting with Management
-
Canaccord Genuity Maintains a 'Hold' on Dendreon (DNDN); Cutting Estimates After Q1 Results
-
Leerink Swann Downgrades Dendreon (DNDN) to Market Perform; Modest Growth and Building Competition Becomes Concerning
-
Dendreon Corp (DNDN) Posts Better-Than-Expected Q1 Loss of 59c/Share
-
Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect
-
Canaccord Genuity Cuts Price Target on Dendreon (DNDN) After Q4, But Keeps Buy Rating
-
Goldman Sachs Said Q4 Call Again Raises Dendreon (DNDN) Provenge Concerns
-
Baird Maintains a 'Neutral' on Dendreon (DNDN); Provenge Inflection Point Still Lacking
-
Brean Murray Carret & Co. Debates Survival of Dendreon (DNDN) Long-Term with Oral Competition; Maintains 'Sell'
-
Dendreon (DNDN) Shares Rocked Despite Strong Q4 Numbers
-
Dendreon (DNDN) March calls active as shares sell off on Q4 and outlook
-
Dendreon Corp (DNDN) Reports Very Strong Q4 Results
-
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
-
Dendreon (DNDN) Surges After Sales, Commercialization Update
-
Dendreon (DNDN) Q4 Product Revs Rise 230% to $82M, Shy of Views
-
Dendreon (DNDN) Sees 'Addressable Population' in Europe Similar to US; Affirms 'Modest' Provenge Growth in Q4
-
Dendreon Corp (DNDN) Posts Q3 Loss of $0.56, Sales Top Expectations
-
Heading into Q311, Here are Top Five Q211 Earnings Winners and Losers
-
Dendreon (DNDN) to Discuss Restructuring Plan on Call Tomorrow, Sept. 8th at 4:30pm ET
-
Dendreon (DNDN) Posts Narrower than Expected Q2 Loss; Withdraws PROVENGE Guidance
-
Dendreon Corp. (DNDN) Reports Smaller Than Expected Q1 Loss
-
Dendreon Corp. (DNDN) Reports Q4 Loss of 64c
-
Dendreon (DNDN) Reports Winder Q3 Loss, On Lower Sales - Stock Halted
-
Dendreon (DNDN) Reports Q1 Loss of 96c
-
Dendreon Corp. (DNDN) Posts Q4 Loss of $0.28, In-Line With Views; Revs Miss
-
Dendreon (DNDN) Reports Q3 Loss of $0.40, Misses by 19c
-
Dendreon (DNDN) Reports Q1 Loss of $0.16, Beats by 2c
-
Dendreon (DNDN) Reports Q4 Loss of $0.09
-
Dendreon (DNDN) Reports Mixed Q2 Results
-
Dendreon (DNDN) Misses Q1 EPS by 1c, Revs Light
Back to DNDN Stock Lookup
